Taylor Wessing advises on new financing to enhance novel stent technology
The venture capital and life sciences groups at industry leading law firm, Taylor Wessing LLP, have advised new client, Seroba Kernel Life Sciences, on its Series A equity financing in Veryan Holdings Limited, a developer of novel stent technology.
Seroba Kernal, a European life sciences venture capital firm, led the €4 million funding round, with other investors including Imperial Innovations, Oxford Capital Partners and NESTA. The funds will be used to finance further development activities and a pivotal clinical trial designed to demonstrate the clinical benefit of Veryan's stent technology.
Taylor Wessing is a leading firm in the technology sector in Europe, with particular focus on life sciences and healthcare industries, including medical devices. The firm is traditionally strong in advising IP and technology-rich industries, with an industry specific approach that combines the strength of the firm's IP expertise with the transactional experience of its corporate department.
The firm has recently won industry awards for both its venture capital and life sciences expertise, including: European Life Sciences IP Firm of the Year at the Managing Intellectual Property Awards (2008); and Law Firm of the Year at the European Venture Capital Journal Awards (2008).
The Taylor Wessing team advising Seroba Kernel was led by Simon Walker (Partner, Venture Capital), assisted by Susanna Stanfield (Senior Associate, Venture Capital), Malcolm Bates (Partner, Life Sciences), Ann Casey (Partner, Share Options) and Oliver Loach (Associate, Employment).
Ends
Lawyers Simon Walker, Malcolm Bates, Ann Casey
Notes to editors
For more information or to speak to Simon Walker, please contact Sarah le Cheminant at Taylor Wessing:
Tel: +44 (0)20 7300 4930
Email: s.lecheminant@taylorwessing.com
Taylor Wessing LLP is a leading law firm providing support for commercial organisations doing business in Europe, the Middle East and China.
www.taylorwessing.com
Seroba Kernel Life Sciences Limited (Seroba Kernel) is a European life science venture capital firm with total funds under management of €100m. In 2009, the firm made a first close of its pan-European Seroba Kernel Life Sciences Fund II with over €75 million in committed capital. Seroba Kernel and partner firm kernel Capital have in excess of €190 million under management.
Seroba Kernel invests across the spectrum of the life science industry including biotechnology, specialty pharmaceuticals, medical technology, diagnostics, instrumentation and other selected opportunities within the sector that have the potential to fundamentally change medical care. The fund focuses on innovative opportunities that closely match market needs, investing on average €5 to €7 million over the life of each investment.
